Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suzhou Zelgen Biopharmaceuticals CoSHSE:688266 +1.39%69 Cyclically Adjusted PB Ratio is 36.89 as of Aug. 28, 2026, which is 33% above its 10-year median of 27.79. GuruFocus rates SHSE:688266 with a GF Score™ of 69/100 and a GF Value™ of ¥221.93 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 683 Biotechnology companies, Suzhou Zelgen Biopharmaceuticals Co ranks worse than 97.8% on this metric.
The historical rank and industry rank for Suzhou Zelgen Biopharmaceuticals Co's Cyclically Adjusted PB Ratio or its related term are showing as below:
SHSE:688266'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 24 Med: 27.79 Max: 39.12
Current: 39.12
During the past 10 years, Suzhou Zelgen Biopharmaceuticals Co's highest Cyclically Adjusted PB Ratio was 39.12. The lowest was 24.00. And the median was 27.79.
SHSE:688266's Cyclically Adjusted PB Ratio is ranked worse than 97.8% of 683
companies
in the Biotechnology industry
Industry Median: 1.61
vs SHSE:688266: 39.12
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Suzhou Zelgen Biopharmaceuticals Co's adjusted book value per share data of for the fiscal year that ended in Dec25 was ¥4.082. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ¥3.29 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Suzhou Zelgen Biopharmaceuticals Co Cyclically Adjusted PB Ratio Related Terms
Suzhou Zelgen Biopharmaceuticals Co Cyclically Adjusted PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Zelgen Biopharmaceuticals Co Cyclically Adjusted PB Ratio Chart
SHSE:688266 vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Suzhou Zelgen Biopharmaceuticals Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Zelgen Biopharmaceuticals Co Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Suzhou Zelgen Biopharmaceuticals Co's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Suzhou Zelgen Biopharmaceuticals Co's Cyclically Adjusted PB Ratio falls into.
Suzhou Zelgen Biopharmaceuticals Co Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 36.89 mean?
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) has a Cyclically Adjusted PB Ratio of 36.89 as of Aug. 28, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. This is 33% above median its historical median of 27.79. Over the past decade, Suzhou Zelgen Biopharmaceuticals Co's Cyclically Adjusted PB Ratio has ranged from 24.00 to 39.12. According to the industry distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #668 out of 683 companies in the Biotechnology industry, placing it in the top 97.8%.
Is Suzhou Zelgen Biopharmaceuticals Co's Cyclically Adjusted PB Ratio too high?
Suzhou Zelgen Biopharmaceuticals Co's current Cyclically Adjusted PB Ratio of 36.89 is 33% above median its 10-year median of 27.79. Over the past 10 years, this metric has ranged from a low of 24.00 to a high of 39.12. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.61. Suzhou Zelgen Biopharmaceuticals Co's value of 36.89 is 2191.3% above this industry median. Based on the distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #668 out of 683 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Suzhou Zelgen Biopharmaceuticals Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Zelgen Biopharmaceuticals Co's Cyclically Adjusted PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #668 out of 683 companies for Cyclically Adjusted PB Ratio. This places Suzhou Zelgen Biopharmaceuticals Co in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.61. Suzhou Zelgen Biopharmaceuticals Co's value of 36.89 is 2191.3% above this benchmark. Historically, Suzhou Zelgen Biopharmaceuticals Co's own Cyclically Adjusted PB Ratio has ranged from 24.00 to 39.12 over the past decade. While the company's 10-year median is 27.79 vs. the industry median of 1.61, Suzhou Zelgen Biopharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.61, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Zelgen Biopharmaceuticals Co's current Cyclically Adjusted PB Ratio of 36.89 is 2191.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Zelgen Biopharmaceuticals Co's current Cyclically Adjusted PB Ratio is 36.89, which is 33% above median its own 10-year median of 27.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Zelgen Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥221.93, compared to a current price of ¥121.36 — trading 45.3% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 36.89, which is 33% above median its 10-year median of 27.79 and 2191.3% above the Biotechnology industry median of 1.61. Suzhou Zelgen Biopharmaceuticals Co's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266), the current Cyclically Adjusted PB Ratio is 36.89 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥121.36 is trading 45.3% below its estimated GF Value™ of ¥221.93.
GuruFocus considers Suzhou Zelgen Biopharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for SHSE:688266:
Cyclically Adjusted PB Ratio: 36.89 (33% above median its 10-year median of 27.79)
GF Value™: ¥221.93 vs. price of ¥121.36 (45.3% below fair value)
Industry Position: 2191.3% above the Biotechnology median (#668 of 683)
No single metric tells the full story. See the SHSE:688266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
69GF Score
Get the complete analysis for SHSE:688266
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688266 has been successfully added to your 
